Is it possible to regress atherosclerotic lesions with long-term treatment with lipoprotein apheresis?
https://doi.org/10.15829/1560-4071-2024-6069
EDN: GFQSRX
Abstract
The article presents the up-to-date information on the effect of lipoprotein apheresis (LA) on atherosclerotic lesions. Some studies using modern diagnostic imaging techniques (such as intravascular ultrasound or magnetic resonance imaging) have clearly demonstrated plaque regression. Coronary angiography has also seen reversal or at least slow plaque progression. Plaque regression likely leads to a decrease in the incidence of atherosclerotic cardiovascular events (CVEs). However, this has not yet been fully proven. Recent data indicate that reduction in low-density lipoprotein cholesterol and lipoprotein(a) levels is not a major factor in reducing the incidence of atherosclerotic CVEs in patients undergoing extracorporeal treatment. The most significant risk factors in this case are older age and a greater CVE rate observed before the start of LA, as well as smoking. New studies using modern diagnostic imaging methods in patients receiving LA are necessary.
About the Authors
Ulrich Julius
Center for Lipidology and Lipoprotein Apheresis, Department of Internal Medicine III, Carl Gustav Carus University Hospital of the Dresden University of Technology
Germany
Competing Interests:
Germany
Dresden
Competing Interests:
None
Sergey Tselmin
Center for Lipidology and Lipoprotein Apheresis, Department of Internal Medicine III, Carl Gustav Carus University Hospital of the Dresden University of Technology
Germany
Competing Interests:
Germany
Dresden
Competing Interests:
None
V. A. Korneva
Petrozavodsk State University
Russian Federation
Competing Interests:
Russian Federation
Petrozavodsk
Competing Interests:
None
References
1. Julius U. History of lipidology and lipoprotein apheresis. Atheroscler Suppl. 2017;30:1-8. doi:10.1016/j.atherosclerosissup.2017.05.034.
2. Thompson GR. LDL apheresis. Atherosclerosis. 2003;167(1):1-13. doi:10.1016/s0021-9150(02)00251-4.
3. Dawson L, Lum M, Nerleker, N, et al. Coronary Atherosclerotic Plaque Regression: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79:66-82. doi:10.1016/j.jacc.2021.10.035.
4. Klingel R, Heibges A, Fassbender C. Lipoprotein apheresis results in plaque stabilization and prevention of cardiovascular events: comments on the prospective Pro(a)LiFe study. Clin Res Cardiol Suppl. 2015;10:46-50. doi:10.1007/s11789-015-0068-y.
5. Nissen SE, Tuzcu, EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071-80. doi:10.1001/jama.291.9.1071.
6. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556-65. doi:10.1001/jama.295.13.jpc60002.
7. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365:2078-87. doi:10.1056/NEJMoa1110874.
8. Park SJ, Kang SJ, Ahn JM, et al. Effect of Statin Treatment on Modifying Plaque Composition: A Double-Blind, Randomized Study. J Am Coll Cardiol. 2016;67:1772-83. doi:10.1016/j.jacc.2016.02.014.
9. Underhill HR, Yuan C, Zhao XQ, et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J. 2008;155:584 e1-8. doi:10.1016/j.ahj.2007.11.018.
10. Tsujita K, Sugiyama S, Sumida H, et al. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial. J Am Coll Cardiol. 2015;66:495-507. doi:10.1016/j.jacc.2015.05.065.
11. Hougaard M, Hansen HS, Thayssen P, et al. Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovasc Revasc Med. 2017;18:110-7. doi:10.1016/j.carrev.2016.11.010.
12. Mirzaee S, Thein PM, Nogic J, et al. The effect of combined ezetimibe and statin therapy versus statin therapy alone on coronary plaque volume assessed by intravascular ultrasound: A systematic review and meta-analysis. J Clin Lipidol. 2018;12:1133-40.e15. doi:10.1016/j.jacl.2018.06.001.
13. Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016;316:2373-84. doi:10.1001/jama.2016.16951.
14. Nicholls SJ, Kataoka Y, Nissen SE, et al. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. JACC Cardiovasc Imaging. 2022;15:1308-21. doi:10.1016/j.jcmg.2022.03.002.
15. Chen J, Zhao F, Lei C, et al. Effect of evolocumab on the progression of intraplaque neovascularization of the carotid based on contrast-enhanced ultrasonography (EPIC study): A prospective single-arm, open-label study. Front Pharmacol. 2022;13:999224. doi:10.3389/fphar.2022.999224.
16. Wu L, Kong Q, Huang H, et al. Effect of PCSK9 inhibition in combination with statin therapy on intracranial atherosclerotic stenosis: A high-resolution MRI study. Front Aging Neurosci. 2023;15:1127534. doi:10.3389/fnagi.2023.1127534.
17. Ogata A, Oho K, Matsumoto N, et al. Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab. Acta Neurochir (Wien). 2019;161:597-600. doi:10.1007/s00701-019-03825-4.
18. Perez de Isla L, Diaz-Diaz JL, Romero MJ, et al. Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study. Circulation. 2023;147:1436-43. doi:10.1161/CIRCULATIONAHA.122.062557.
19. Raber L, Ueki Y, Otsuka T, et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA. 2022;327:1771-81. doi:10.1001/jama.2022.5218.
20. Biccire FG, Haner J, Losdat S, et al. Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy. J Am Coll Cardiol. 2023;82:1737-47. doi:10.1016/j.jacc.2023.08.019.
21. Akers EJ, Nicholls SJ, Di Bartolo BA. Plaque Calcification: Do Lipoproteins Have a Role? Arterioscler Thromb Vasc Biol. 2019;39:1902-10. doi:10.1161/ATVBAHA.119.311574.
22. Kong N, Xu Q, Cui W, et al. PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis. Ann Transl Med. 2022;10:1205. doi:10.21037/atm-22-4652.
23. Wu NQ, Li ZF, Lu MY, Li JJ. Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups. Expert Opin Biol Ther. 2024;24:157-69. doi:10.1080/14712598.2024.2321374.
24. Matsuzaki M, Hiramori, K, Imaizumi, T, et al. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). J. Am. Coll. Cardiol. 2002;40:220-7. doi:10.1016/s0735-1097(02)01955-1.
25. Banerjee S, Luo P, Reda DJ, et al. Plaque Regression and Endothelial Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER). Circ Cardiovasc Interv. 2020;13:e008933. doi:10.1161/CIRCINTERVENTIONS.119.008933.
26. Safarova MS, Ezhov MV, Afanasieva OI, et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler. Suppl. 2013;14:93-99. doi:10.1016/j.atherosclerosissup.2012.10.015.
27. Roeseler E, Julius U, Heigl F, et al. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization. Arterioscler Thromb Vasc Biol. 2016;36:2019-27. doi:10.1161/ATVBAHA.116.307983.
28. Klingel R, Heibges A, Fassbender C. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease—Additional particular aspects of the Pro(a)LiFe multicenter trial. Atheroscler. Suppl. 2015;18:35-40. doi:10.1016/j.atherosclerosissup.2015.02.012.
29. Klingel R, Heibges A, Fassbender C, ProLiFe-Study G. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines. Clin Res Cardiol Suppl. 2017;12:38-43. doi:10.1007/s11789-017-0082-3.
30. Grimm JM, Nikolaou K, Schindler A, et al. Characteristics of carotid atherosclerotic plaques of chronic lipid apheresis patients as assessed by in vivo high-resolution CMR—a comparative analysis. J. Cardiovasc. Magn Reson. 2012;14:80. doi:10.1186/1532-429X-14-80.
31. Khan TZ, Hsu LY, Arai AE, et al. Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial. Eur. Heart J. 2017;38:1561-9. doi:10.1093/eurheartj/ehx178.
32. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;41:111-88. doi:10.1093/eurheartj/ehz455.
33. Korneva V, Kuznetsova T, Julius U. Can Recently Recommended Target Levels for LDL-Cholesterol and Lipoprotein(a) Be Reached by Using Intensive Lipid-Lowering Therapy Including Lipoprotein Apheresis? Medp Cardiol Vasc Med. 2022;2.mpcvm-202205001.
34. Julius U, Kuss S, Tselmin S, et al. Why Some Patients Undergoing Lipoprotein Apheresis Therapy Develop New Cardiovascular Events? J Cardiovasc Dev Dis. 2020;7. doi:10.3390/jcdd7030025.
35. Mabuch H, Koizumi J, Shimizu M, et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am. J. Cardiol. 1998;82:1489-95.
36. Jaeger BR, Richte Y, Nagel D, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med. 2009;6:229-39. doi:10.1038/ncpcardio1456.
37. Leebmann J, Roeseler E, Julius U, et al. Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease: Prospective Observational Multicenter Study. Circulation. 2013;128:2567-76. doi:10.1161/CIRCULATIONAHA.113.002432.
38. Schettler VJJ, Peter C, Zimmermann T, et al. The German Lipoprotein Apheresis Registry-Summary of the ninth annual report. Ther Apher Dial. 2022;26 Suppl 1:81-8. doi:10.1111/1744-9987.13780.
39. Kuss SFR, Schatz U, Tselmin S, et al. The development of lipoprotein apheresis in Saxony in the last years. Ther Apher Dial. 2022;26 Suppl 1:53-63. doi:10.1111/1744-9987.13940.
40. von Dryander M, Fischer S, Passauer J, et al. Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern. Atheroscler. Suppl. 2013;14:39-44. doi:10.1016/j.atherosclerosissup.2012.10.005.
41. Schatz U, Tselmin S, Muller G, et al. Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels — A multicenter observational study. Atheroscler Suppl. 2017;30:246-52. doi:10.1016/j.atherosclerosissup.2017.05.047.
42. Sachais BS, Shaz BH. Apheresis to Mitigate Atherosclerotic Vascular Disease. Am J Hypertens. 2018;31:945-9. doi:10.1093/ajh/hpy068.
43. Sarraju A, Nissen SE. Atherosclerotic plaque stabilization and regression: a review of clinical evidence. Nat Rev Cardiol. 2024;7:487-97. doi:10.1038/s41569-023-00979-8.
44. Julius U, Tselmin S, Bornstein SR. Lipoprotein apheresis: yesterday, today, tomorrow. Review. Russian Journal of Cardiology. 2018;(8):74-8. (In Engl.) doi:10.15829/1560-4071-2018-8-74-78.
45. Ezhov MV, Bazhan SS, Ershova AI, et al. Clinical guidelines for familial hypercholesterolemia. Ateroscleroz. 2019;15(1):58-98. (In Russ.)
46. Ezhov MV, Barbarash OL, Voevoda MI, et al. Organization of lipid centers operation in the Russian Federation — new opportunities. Russian Journal of Cardiology. 2021;26(6):4489. (In Russ.) doi:10.15829/1560-4071-2021-4489.
47. Afanasieva OI, Ezhov MV, Pokrovsky SN. Antisense oligonucleotides and therapeutical monoclonal antibodies as a basement for novel biological lipidlowering drugs. Russian Journal of Cardiology. 2018;(8):99-109. (In Russ.) doi:10.15829/1560-4071-2018-8-99-109.
Supplementary files
Review
For citations:
Julius U., Tselmin S., Korneva V.A. Is it possible to regress atherosclerotic lesions with long-term treatment with lipoprotein apheresis? Russian Journal of Cardiology. 2024;29(8):6069. (In Russ.) https://doi.org/10.15829/1560-4071-2024-6069. EDN: GFQSRX
Views:
393
Email this article 